Amgen's Positive Results for Tepezza Cause Viridian Therapeutics Stock to Plummet.

Viridian Therapeutics' shares fell 21% to $14.73 after Amgen reported positive results for its eye disease treatment, Tepezza. This follows Viridian's own eye treatment results in March, which led to a decline of over 50% year-to-date. The competition from Amgen's treatment is seen as a negative factor for Viridian.